Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vaccine and biological products in China. The company offers recombinant COVID-19 vaccine; recombinant mycobacterium tuberculosis fusion protein products; group A and C meningococcal polysaccharide vaccine; ACYW135 meningococcal polysaccharide vaccine; Haemophilus Influenza type B conjugate vaccine; mycobacterium injection under the Vaccae brand; and meningococcal group A and C conjugate vaccine. It also provides cold storage, refrigerated vehicles, and cold roll boxes; and customs clearance and registration of imported vaccines. The company was founded in 2002 and is based in Chongqing, China.
Frequently asked questions
What sector does Chongqing Zhifei Bio Products (300122) operate in?
Chongqing Zhifei Bio Products belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Chongqing Zhifei Bio Products (300122) current stock price?
As of the latest data, Chongqing Zhifei Bio Products stock price is CN¥12.21, with a previous close of CN¥12.51. Chongqing Zhifei Bio Products lost -CN¥0.30 in the last trading session, representing a -2.4% loss.
What is Chongqing Zhifei Bio Products (300122) current market capitalization?
Chongqing Zhifei Bio Products market cap is approximately 29.23 billion.
What is Chongqing Zhifei Bio Products (300122) Earnings Per Share (EPS)?
The trailing EPS is -CN¥6.24, and the forward EPS is -CN¥0.42.
Does Chongqing Zhifei Bio Products (300122) pay dividends?
No. Chongqing Zhifei Bio Products does not pay a dividend.
How did Chongqing Zhifei Bio Products (300122) perform in its most recent earnings report?
In the last report (June 30, 2026), Chongqing Zhifei Bio Products posted an EPS surprise of -300% and a revenue surprise of -9.26%.
What is Chongqing Zhifei Bio Products (300122) beta (volatility) score?
Chongqing Zhifei Bio Products has a beta of 0.463, indicating lower volatility than the overall market.
